Cargando…
Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience
Hypo-fractionated radiotherapy and stereotactic body radiotherapy are viable options for treatment of oligometastases. A prodrug of mitomycin-C is under clinical testing as a pegylated liposomal formulation (Promitil) with an improved safety profile over mitomycin-C. Promitil was offered to two pati...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275313/ https://www.ncbi.nlm.nih.gov/pubmed/30534533 http://dx.doi.org/10.3389/fonc.2018.00544 |
_version_ | 1783377799897153536 |
---|---|
author | Tahover, Esther Bar-Shalom, Rachel Sapir, Eli Pfeffer, Raphael Nemirovsky, Igor Turner, Yehonatan Gips, Maya Ohana, Patricia Corn, Benjamin W. Wang, Andrew Z. Gabizon, Alberto A. |
author_facet | Tahover, Esther Bar-Shalom, Rachel Sapir, Eli Pfeffer, Raphael Nemirovsky, Igor Turner, Yehonatan Gips, Maya Ohana, Patricia Corn, Benjamin W. Wang, Andrew Z. Gabizon, Alberto A. |
author_sort | Tahover, Esther |
collection | PubMed |
description | Hypo-fractionated radiotherapy and stereotactic body radiotherapy are viable options for treatment of oligometastases. A prodrug of mitomycin-C is under clinical testing as a pegylated liposomal formulation (Promitil) with an improved safety profile over mitomycin-C. Promitil was offered to two patients with oligometastases from colorectal cancer as radiosensitizer. Each derived durable clinical benefit from Promitil administered immediately prior to and following irradiation. Transient toxicity to normal tissues of moderate to severe degree was observed. Promitil appears to have potential clinical value in this setting. HIGHLIGHTS: - Delivery of radio-sensitizing drugs with pegylated (long-circulating) liposomes is a pharmacologically rational approach which remains largely clinically untested. - A mitomycin-c prodrug delivered by pegylated liposomes (Promitil) is activated by thiol groups, which are produced in excess by radiation-damaged cells, thus potentiating the radio-sensitizing effect of Promitil. - Two durable clinical responses in patient with colorectal oligometastases to Promitil and radiotherapy suggest that this approach may be of value in cancer chemo-radiotherapy. |
format | Online Article Text |
id | pubmed-6275313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62753132018-12-10 Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience Tahover, Esther Bar-Shalom, Rachel Sapir, Eli Pfeffer, Raphael Nemirovsky, Igor Turner, Yehonatan Gips, Maya Ohana, Patricia Corn, Benjamin W. Wang, Andrew Z. Gabizon, Alberto A. Front Oncol Oncology Hypo-fractionated radiotherapy and stereotactic body radiotherapy are viable options for treatment of oligometastases. A prodrug of mitomycin-C is under clinical testing as a pegylated liposomal formulation (Promitil) with an improved safety profile over mitomycin-C. Promitil was offered to two patients with oligometastases from colorectal cancer as radiosensitizer. Each derived durable clinical benefit from Promitil administered immediately prior to and following irradiation. Transient toxicity to normal tissues of moderate to severe degree was observed. Promitil appears to have potential clinical value in this setting. HIGHLIGHTS: - Delivery of radio-sensitizing drugs with pegylated (long-circulating) liposomes is a pharmacologically rational approach which remains largely clinically untested. - A mitomycin-c prodrug delivered by pegylated liposomes (Promitil) is activated by thiol groups, which are produced in excess by radiation-damaged cells, thus potentiating the radio-sensitizing effect of Promitil. - Two durable clinical responses in patient with colorectal oligometastases to Promitil and radiotherapy suggest that this approach may be of value in cancer chemo-radiotherapy. Frontiers Media S.A. 2018-11-26 /pmc/articles/PMC6275313/ /pubmed/30534533 http://dx.doi.org/10.3389/fonc.2018.00544 Text en Copyright © 2018 Tahover, Bar-Shalom, Sapir, Pfeffer, Nemirovsky, Turner, Gips, Ohana, Corn, Wang and Gabizon. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Tahover, Esther Bar-Shalom, Rachel Sapir, Eli Pfeffer, Raphael Nemirovsky, Igor Turner, Yehonatan Gips, Maya Ohana, Patricia Corn, Benjamin W. Wang, Andrew Z. Gabizon, Alberto A. Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience |
title | Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience |
title_full | Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience |
title_fullStr | Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience |
title_full_unstemmed | Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience |
title_short | Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience |
title_sort | chemo-radiotherapy of oligometastases of colorectal cancer with pegylated liposomal mitomycin-c prodrug (promitil): mechanistic basis and preliminary clinical experience |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275313/ https://www.ncbi.nlm.nih.gov/pubmed/30534533 http://dx.doi.org/10.3389/fonc.2018.00544 |
work_keys_str_mv | AT tahoveresther chemoradiotherapyofoligometastasesofcolorectalcancerwithpegylatedliposomalmitomycincprodrugpromitilmechanisticbasisandpreliminaryclinicalexperience AT barshalomrachel chemoradiotherapyofoligometastasesofcolorectalcancerwithpegylatedliposomalmitomycincprodrugpromitilmechanisticbasisandpreliminaryclinicalexperience AT sapireli chemoradiotherapyofoligometastasesofcolorectalcancerwithpegylatedliposomalmitomycincprodrugpromitilmechanisticbasisandpreliminaryclinicalexperience AT pfefferraphael chemoradiotherapyofoligometastasesofcolorectalcancerwithpegylatedliposomalmitomycincprodrugpromitilmechanisticbasisandpreliminaryclinicalexperience AT nemirovskyigor chemoradiotherapyofoligometastasesofcolorectalcancerwithpegylatedliposomalmitomycincprodrugpromitilmechanisticbasisandpreliminaryclinicalexperience AT turneryehonatan chemoradiotherapyofoligometastasesofcolorectalcancerwithpegylatedliposomalmitomycincprodrugpromitilmechanisticbasisandpreliminaryclinicalexperience AT gipsmaya chemoradiotherapyofoligometastasesofcolorectalcancerwithpegylatedliposomalmitomycincprodrugpromitilmechanisticbasisandpreliminaryclinicalexperience AT ohanapatricia chemoradiotherapyofoligometastasesofcolorectalcancerwithpegylatedliposomalmitomycincprodrugpromitilmechanisticbasisandpreliminaryclinicalexperience AT cornbenjaminw chemoradiotherapyofoligometastasesofcolorectalcancerwithpegylatedliposomalmitomycincprodrugpromitilmechanisticbasisandpreliminaryclinicalexperience AT wangandrewz chemoradiotherapyofoligometastasesofcolorectalcancerwithpegylatedliposomalmitomycincprodrugpromitilmechanisticbasisandpreliminaryclinicalexperience AT gabizonalbertoa chemoradiotherapyofoligometastasesofcolorectalcancerwithpegylatedliposomalmitomycincprodrugpromitilmechanisticbasisandpreliminaryclinicalexperience |